Martin Thai, MD
Interventional Pain Medicine · Austin, TXNPI 1871529453
Payments from drug & device makers
Across 494 payments — averaging $46.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- Globus Medical$3K
- Abbott$2K
- Medtronic$2K
- Relievant Medsystems, Inc.$1K
- Nevro Corp.$1K
- plus $4K from 30 others
What the payments were for
- Consulting fees$1,2756%
- Travel & lodging$3,55315%
- Food & beverage$18,34979%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 243 | $9,971 |
| Globus Medical | 36 | $2,893 |
| Abbott | 43 | $2,097 |
| Medtronic | 33 | $1,976 |
| Relievant Medsystems, Inc. | 7 | $1,430 |
| Nevro Corp. | 13 | $1,150 |
| Stryker | 6 | $964 |
| Painteq LLC | 5 | $321 |
| SPR Therapeutics, Inc | 4 | $313 |
| Collegium Pharmaceutical, Inc. | 12 | $231 |
| Novartis | 10 | $188 |
| Biotronik NRO, Inc. | 4 | $176 |
| Nalu Medical, Inc. | 2 | $174 |
| AbbVie | 8 | $159 |
| Amgen(2 entities) | 8 | $119 |
| Teva Pharmaceuticals USA, Inc. | 7 | $113 |
| Arbor Pharmaceuticals, Inc. | 7 | $103 |
| Supernus Pharmaceuticals, Inc. | 6 | $97 |
| Pfizer | 6 | $96 |
| Scilex Pharmaceuticals Inc. | 6 | $89 |
| Azurity Pharmaceuticals, Inc. | 4 | $73 |
| Redhill Biopharma Inc. | 3 | $63 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $57 |
| Almatica Pharma LLC | 3 | $49 |
| Forte Bio-pharma LLC | 2 | $46 |
| Valinor Pharma, LLC | 2 | $45 |
| Si-bone, Inc. | 2 | $34 |
| Lundbeck LLC | 1 | $24 |
| Shionogi Inc | 1 | $22 |
| Vertiflex, Inc. | 1 | $20 |
| Biodelivery Sciences International, Inc. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Orthogenrx Inc. | 1 | $14 |
| AstraZeneca | 1 | $14 |
| BD | 1 | $13 |
| Johnson & Johnson | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Senza$2,892
- Intracept$2,543
- WaveWriter Alpha Prime 16$1,398
- GENERAL - THERAPIES$1,153
- OPTABLATE$755
- SPINEJACK$755
- PROCLAIM$720
- GENERAL PAIN MANAGEMENT$673
- ETERNA$386
- SYNCHROMEDII$351
- Proclaim Family of SCS IPGs$320
- INTELLIS ADAPTIVESTIM$306
- PAINTEQ$208
- INCEPTIV$182
- PRIMEADVANCED SURESCAN$169
- SPRINT PNS System$135
- Nalu Neurostimulation System$132
- SPECTRA WAVEWRITER$125
- Senza Spinal Cord Stimulation System$111
How this compares
$23,178 in reported general payments places this provider in the 80th percentile of 287 interventional pain medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 885 | $28,098 |
| LyricaPregabalin | 11 | $10,030 |
| BelbucaBuprenorphine Hcl | 14 | $7,328 |
| Fentanyl | 23 | $7,155 |
| Nucynta ErTapentadol Hcl | 11 | $7,042 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 230 | $6,912 |
| Buprenorphine | 22 | $5,766 |
| Gabapentin | 333 | $4,191 |
| Pregabalin | 157 | $3,978 |
| Tramadol Hcl ErTramadol Hcl | 46 | $3,382 |
| Oxymorphone Hcl ErOxymorphone Hcl | 13 | $3,000 |
| Morphine Sulfate ErMorphine Sulfate | 120 | $2,983 |
| Diclofenac Sodium | 13 | $2,275 |
| Lidocaine | 13 | $2,105 |
| Tizanidine Hcl | 216 | $1,996 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Belbuca, Nucynta Er | $231 | $14,37025 claims |
| PfizerLyrica | $96 | $10,03011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 287 interventional pain medicine providers in Texas.
Other interventional pain medicine in Austin
- Genaro GutierrezAustin$1.3M
- Brannon FrankAustin$698K
- Anjuli DesaiAustin$82K
- Paul leAustin$27K
- Clayton AdamsAustin$22K
- Gabor RaczLubbock$3M
- Pankaj MehtaKilleen$2.2M
- Chad StephensSouthlake$1.1M
- Ioannis SkaribasHouston$979K
- Duane GriffithTyler$730K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.